Davis Polk advised the lenders in connection with a $3 billion 364-day term loan credit facility for AbbVie Inc. 

Headquartered in Chicago, Illinois, AbbVie is a global research-based biopharmaceutical company that develops and markets advanced therapies that address some of the world’s most complex and serious diseases. AbbVie products are used to treat chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease; hepatitis C; human immunodeficiency virus; endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions, such as low testosterone.

The Davis Polk finance team included partner Jason Kyrwood and associate Matthew W. Levy. Counsel Jeanine P. McGuinness provided regulatory advice. Counsel David Mollo-Christensen and Charles Shi provided executive compensation advice. Partner David H. Schnabel and associates Christopher A. Baratta and James Manzione provided tax advice. Members of the Davis Polk team are based in the New York and Washington DC offices.

Copy link to share post